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Abstract
Background: n-3 polyunsaturated fatty acids, namely docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), reduce
the risk of cardiovascular disease and can ameliorate many of obesity-associated disorders. We hypothesised that the latter
effect will be more pronounced when DHA/EPA is supplemented as phospholipids rather than as triglycerides.
Methodology/Principal Findings: In a ‘prevention study’, C57BL/6J mice were fed for 9 weeks on either a corn oil-based
high-fat obesogenic diet (cHF; lipids ,35% wt/wt), or cHF-based diets in which corn oil was partially replaced by DHA/EPA,
admixed either as phospholipids or triglycerides from marine fish. The reversal of obesity was studied in mice subjected to
the preceding cHF-feeding for 4 months. DHA/EPA administered as phospholipids prevented glucose intolerance and
tended to reduce obesity better than triglycerides. Lipemia and hepatosteatosis were suppressed more in response to
dietary phospholipids, in correlation with better bioavailability of DHA and EPA, and a higher DHA accumulation in the liver,
white adipose tissue (WAT), and muscle phospholipids. In dietary obese mice, both DHA/EPA concentrates prevented
a further weight gain, reduced plasma lipid levels to a similar extent, and tended to improve glucose tolerance. Importantly,
only the phospholipid form reduced plasma insulin and adipocyte hypertrophy, while being more effective in reducing
hepatic steatosis and low-grade inflammation of WAT. These beneficial effects were correlated with changes of
endocannabinoid metabolome in WAT, where phospholipids reduced 2-arachidonoylglycerol, and were more effective in
increasing anti-inflammatory lipids such as N-docosahexaenoylethanolamine.
Conclusions/Significance: Compared with triglycerides, dietary DHA/EPA administered as phospholipids are superior in
preserving a healthy metabolic profile under obesogenic conditions, possibly reflecting better bioavalability and improved
modulation of the endocannabinoid system activity in WAT.
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Introduction
Obesity and associated diseases such as type 2 diabetes,
dyslipidemia and hypertension, i.e. components of the metabolic
syndrome [1], are a major public health problem. While effective
pharmacological interventions for the treatment of obesity-
associated diseases require the use of multiple agents and are
often associated with adverse side-effects, lifestyle modifications
remain an essential component of treatment strategies. In this
respect, dietary intake of marine fish oils, namely long-chain n-3
polyunsaturated fatty acids (LC n-3 PUFA) such as docosahex-
aenoic acid (DHA; 22:6n-3) and eicosapentaenoic acid (EPA;
20:5n-3), have been shown to exert profound hypolipidemic effects
[2,3], reducing systemic inflammation [4,5] as well as low-grade
inflammation of white adipose tissue (WAT; [6–9]) and limiting
hepatosteatosis [8–12], resulting in a decrease in cardiovascular
morbidity and the incidence of type 2 diabetes in humans [13,14].
The cardioprotective effects have been especially pronounced in
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diabetic patients who have had myocardial infarction [15].
However, in spite of the fact that LC n-3 PUFA could help to
reduce obesity in humans [16,17] and prevent insulin resistance in
rodents [8,18], they do not reverse insulin resistance in diabetic
patients [19].
Metabolic effects of LC n-3 PUFA largely depend on
modulation of gene expression mediated by a peroxisome
proliferator-activated receptor (PPAR)-a, -d (-b), liver X re-
ceptor-a, hepatic nuclear factor-4, and sterol regulatory element-
binding protein-1 [20], as well as on the induction of adiponectin
[3,21] and production of eicosanoids and other lipid mediators
from PUFA [9,20,22]. Also the activity of endocannabinoid system
[23], which is dysregulated in obesity [24], is modulated in
response to LC n-3 PUFA intake. Thus, overactivity of the
endocannabinoid system in tissues of genetically obese fa/fa rats
[25] and mice with high-fat diet-induced obesity [11,26] was
counteracted by LC n-3 PUFA administered as phospholipids in
krill oil. The inhibition of the endocannabinoid system activity
leads to beneficial metabolic effects, reflecting multiple mechan-
isms of endocannabinoid action mediated by their specific
receptors as well as by PPAR-a (reviewed in [23,27]).
Compared with fish oil, containing LC n-3 PUFA as triglycer-
ides, krill oil was more effective in reducing the levels of two major
endogenous ligands, 2-arachidonoylglycerol (2-AG) and ananda-
mide (AEA), containing arachidonic acid (AA; 20:4n-6) in their
backbone, in visceral adipose tissue and in the liver and heart,
respectively [25]. Krill oil also improved blood lipid levels and
reduced hepatic steatosis and glycemia in the obese mice [11,26].
It is likely that supplementation of LC n-3 PUFA as phospholipids
exerts stronger biological effects compared with the triglyceride
form because (i) various phospholipid species can also act as
ligands for nuclear receptors, such as PPAR-a [28], steroidogenic
factor-1, and liver receptor homolog-1 [29], which are involved in
the transcriptional regulation of steroidogenesis and cholesterol
metabolism; and (ii) the phospholipid form has been shown to
augment the bioavailability of DHA and EPA in both rodents [30–
32] and humans [33–35].
In the context of animal models of metabolic syndrome,
experiments focused on the modulation of tissue endocannabi-
noid levels by krill oil have been performed [11,26]. However,
direct comparison of the effects of the triglyceride and
phospholipid forms of LC n-3 PUFA supplementation was only
carried out in the fa/fa rats fed a chow diet [25], while a similar
experiment using a model of diet-induced obesity has not been
performed to date. In humans, no studies exist of the potential
benefits of the phospholipid form of LC n-3 PUFA delivery with
respect to the prevention and treatment of obesity-associated
diseases.
Here, we examined the efficacy of various forms of LC n-3
PUFA in both the prevention and reversal of obesity and
associated metabolic disorders induced by high-fat feeding in
obesity-prone C57BL/6J mice. The results suggest that dietary
DHA and EPA in the form of marine fish phospholipids are
superior to triglycerides with respect to the preservation of
glucose homeostasis and the reversal of hepatic steatosis,
adipocyte hypertrophy and low-grade WAT inflammation.
The higher efficacy of LC n-3 PUFA administered as
phospholipids was associated with their better bioavailability,
and with a relatively strong suppression of the levels of major
endocannabinoids in WAT and plasma, suggesting that mod-
ulation of the endocannabinoid system activity contributed to
their superior efficacy when compared to triglyceride form of
LC n-3 PUFA.
Results
Prevention of Obesity-associated Disorders
To characterise the efficacy of LC n-3 PUFA in the prevention
of adverse consequences of high-fat intake (Fig. 1), three-month-
old mice were fed for a 9-week-period either on a corn oil-based
high-fat diet (cHF diet; lipids , 35% wt/wt) or treated by
isocaloric cHF-based diets with DHA/EPA supplemented as
triglycerides (30 g DHA/EPA per kg diet; cHF+v3TG diet) or
phospholipids (10 or 30 g DHA/EPA per kg diet; cHF+v3PL
diet; Table S1, S2). Thus, in terms of fatty acid composition of
experimental diets (Table S3), the ratio of total n-6 PUFA to total
n-3 PUFA was 3.6 : 1 and 2.9 : 1 in the cHF+v3TG and
cHF+v3PL diet (matched for DHA/EPA content of 30 g of
DHA/EPA per kg diet), respectively. In contrast, this ratio was
much higher (10.3 : 1) in the cHF+v3PL diet containing only 10 g
of DHA/EPA per kg diet (Table S3).
No significant effects of dietary LC n-3 PUFA treatments on
daily food intake were observed (Table 1). Compared with mice
fed the low-fat standard diet (Chow; Table 1 and refs. [8–10,12]),
cHF feeding induced a moderate weight gain without a significant
effect on blood lipid levels, but it altered glucose homeostasis.
While the cHF+v3TG-treatment mainly decreased plasma non-
esterified fatty acid (NEFA) levels, the cHF+v3PL-treatment
showed a strong tendency to lower body weight gain and to reduce
adiposity and adipocyte size, as well as exerting significant
hypolipidemic effects (Table 1). Neither glycemia nor insulinemia
were significantly changed in response to any of the treatments
(Table 1). Importantly, glucose tolerance assessed as area under
the glucose curve (AUC) was only improved in response to the
cHF+v3PL-treatment (Table 1 and Fig. S1), independently of the
dietary DHA/EPA content. Both treatments tended to increase
plasma levels of high-molecular weight (HMW) form of adipo-
nectin. However, only the cHF+v3PL-treatment resulted in lower
lipid accumulation in the liver at both dietary DHA/EPA
concentrations (Table 1).
The above data documented that LC n-3 PUFA supplemented
as phospholipids could preserve ‘healthy’ phenotype during the
development of moderate obesity with greater efficacy than the
triglyceride form.
Bioavailability of DHA and EPA and Changes in Fatty Acid
Composition of Tissue Lipids
In order to analyse the bioavailability of dietary DHA and EPA,
the fatty acid composition of plasma lipids was evaluated by gas
chromatography [36] in mice treated for two weeks with
cHF+v3TG and cHF+v3PL diets at different levels of supple-
mentation with the respective LC n-3 PUFA concentrate (Fig. 2).
For both types of treatments, a positive correlation was found
between dietary concentration and the increment in plasma DHA
and EPA concentration, which was non-linear for DHA (Fig. 2A)
and linear for EPA (Fig. 2B). Accordingly, in the prevention study,
plasma concentrations of both DHA and EPA were higher in the
cHF+v3PL-treated mice than in the cHF+v3TG-treated mice
when compared at the same DHA/EPA dietary concentration (i.e.
30 g per kg diet). However, the difference was greater in the case
of EPA (Fig. 2C,D and Table S4). At the tissue level, DHA as well
as EPA concentrations in the triglyceride fraction either from the
liver or total WAT lipids did not differ between the treatments;
however, EPA was enriched in hepatic phospholipids of the
cHF+v3PL-treated mice (Fig. 2C,D and Tables S5, S6, S7).
A complex evaluation of fatty acid profiles in various lipid
fractions carried out using orthogonal partial least squares-
discriminant analysis (oPLS-DA; Fig. S2 A-D) revealed that, in
n-3 PUFA as Phospholipids
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the case of hepatic phospholipids, namely AA, DHA and EPA
contributed to the separation between the diets (Fig. S2 A,B and
Table S6). In the case of total WAT lipids, linoleic acid (LA;
C18:2), palmitic acid (C16:0), oleic acid (C18:1) and DHA
contributed to the separation of all three dietary groups (Fig. S2
C,D), but only linoleic and palmitic acid levels differed signifi-
cantly between the cHF+v3TG- and cHF+v3PL-treated mice
(Table S7). This probably reflects the dietary content (Table S3).
The above results prompted us to increase the resolution of the
analysis by performing time-of-flight secondary ion mass spec-
trometry (TOF-SIMS; [37,38]) on the liver, WAT and skeletal
muscle of animals fed on cHF+v3TG and cHF+v3PL diets
(matched for the DHA/EPA content; 30 g per kg diet). This
approach enabled the semi-quantitative detection of free fatty
acids and phospholipid, triglycerides, and diacylglycerol species
that differed in the total length of their side chains (for all the data,
see Tables S8, S9, S10). Score plots showed a clear separation
between the diets in all tissues examined (Fig. 3A–C). Next, lipid
molecules were identified that distinguish the effects of diets within
different tissues (Fig. 3D–F), with six of them showing a difference
in concentration between the cHF+v3TG- and cHF+v3PL-
treated mice in at least two of the tissues analysed (Fig. 3G).
Several phospholipid species with polyunsaturated side chains
probably containing DHA [i.e. phosphatidylethanolamine (PE)
38:6, PE 40:6, phosphatidylinositol (PI) 40:6, and phosphatidyl-
choline (PC) 38:6] or EPA (any of the above-mentioned analytes
plus PI38:5) as one of fatty acids bound, as well as diacylglycerol
36:4 (possibly containing AA), discriminated between the
cHF+v3TG- and cHF+v3PL-treated mice. For other less
important lipid species that discriminated between the treatments,
see Fig. S3.
Thus, the superior efficacy of dietary LC n-3 PUFA adminis-
tered as phospholipids in terms of counteracting adverse effects of
developing obesity was linked to the improved bioavailability of
DHA and EPA, and to the accumulation of these fatty acids in
phospholipids in metabolically relevant tissues. In a further
experiment, we sought to characterise the effects of LC n-3 PUFA
supplementation in a setting of established dietary obesity.
Reversal of Dietary Obesity and Associated Disorders
Whether the lipid form of dietary LC n-3 PUFA could influence
the efficacy of these fatty acids in reversing obesity and associated
disorders was studied in mice fed a cHF diet for four months prior
to dietary treatment by a cHF+v3TG or cHF+v3PL diet for nine
weeks. In this experiment, cHF+v3TG or cHF+v3PL diets were
matched for DHA/EPA content (30 g per kg). To mimic a typical
situation in overweight or obese, insulin resistant type 2 diabetic
subjects, all diets were also supplemented by metformin (2 g per
kg). Of note, there were no significant differences between the
control metformin-supplemented cHF diet and the cHF diet alone
with regard to metabolic parameters shown in Table 2. Both
cHF+v3TG- and cHF+v3PL-treatment decreased weight gain,
with a stronger effect being exerted by the cHF+v3PL-treatment,
while food intake was not significantly affected by either treatment
(Table 2). Both treatments reduced adiposity to a similar extent as
well as the levels of plasma lipids, they suppressed glycemia in both
Figure 1. Timeline of dietary studies. All mice were weaned on Chow diet at 4 weeks of age. In the ‘prevention’ and ‘bioavailability’ studies, 3-
month-old mice were switched from Chow to cHF, cHF+v3TG and cHF+v3PL diets for a period of 2 or 9 weeks, respectively, as indicated. In the
‘reversal study’, mice were fed cHF diet for a period of 4 month, followed by 9-week-feeding using cHF, cHF+v3TG and cHF+v3PL diets. In the
‘bioavailability’ study, cHF+v3TG and cHF+v3PL diets with several different concentrations of DHA and EPA were used (see Methods and
Figure 2A,B), while in the ‘prevention’ and ‘reversal’ studies these diets were matched for their DHA/EPA content (i.e. 30 g DHA/EPA per kg diet),
except for the ‘prevention’ study, in which a subgroup of mice was also treated using cHF+v3PL diet containing 10 g DHA/EPA per kg diet. See
Methods for further details. IPGTT, intraperitoneal (i.p.) glucose tolerance tests.
doi:10.1371/journal.pone.0038834.g001
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fed and fasted mice, and they tended to improve glucose tolerance.
Plasma insulin levels discriminated between the two treatments,
with the cHF+v3PL mice showing lower levels (Table 2). Both
treatments induced adiponectin to a similar extent and lowered
muscle lipid content (Table 2).
Histological analysis (Fig. 4A–C) and quantification of tissue
lipids (Fig. 4D) documented that a cHF diet caused a marked
hepatic steatosis (Fig. 4A), which was ameliorated by the
cHF+v3TG-treatment (Fig. 4B,D) and even more strongly by
the cHF+v3PL-treatment (Fig. 4C,D). These anti-steatotic effects
were associated with increased hepatic expression of fatty acid
oxidation genes (Fig. 4E) and down-regulation of lipogenic genes
(Fig. 4F), while the latter effect was stronger in the cHF+v3PL-
treated mice.
Immunohistochemical analysis of WAT (Fig. 5A–C) and
adipocyte morphometry (Fig. 5D) revealed adipocyte hypertrophy
in the cHF-fed mice (compare with Table 1), which was only
significantly reduced by the cHF+v3PL-treatment. WAT macro-
phage infiltration was significantly reduced by cHF+v3TG-
treatment and even more by cHF+v3PL-treatment (Fig. 5E).
Adipose tissue gene expression of monocyte chemoattractant
protein-1 (MCP1; Fig. 5F) and macrophage marker CD68 (not
shown) were reduced to a similar extent by both treatments.
The above data document similar beneficial effects of
cHF+v3TG- and cHF+v3PL-treatment on obesity, lipid metab-
olism and glucose homeostasis in a reversal of obesity setting.
However, the cHF+v3PL-treatment was more efficient as regards
the anti-steatotic effect on the liver and suppression of adipocyte
hypertrophy and low-grade inflammation of WAT in obese mice.
Endocannabinoids in Dietary Obese Mice
Reflecting (i) the pronounced differential effects of cHF+v3TG-
and cHF+v3PL-treatment on the liver and WAT of mice in the
reversal study, and (ii) the association of the beneficial effects of LC
n-3 PUFA administered as phospholipids with the modulation of
endocannabinoid system in WAT but not in the liver [26], the
levels of endocannabinoids and endocannabinoid-like molecules
were assessed in epididymal WAT of dietary obese mice (Fig. 6
and Table S11).
Compared with cHF-fed mice, only the cHF+v3PL-treatment
significantly reduced 2-AG levels (Fig. 6A). Levels of AEA, which
were already relatively low in the cHF-fed mice, were further
Table 1. Prevention of obese phenotype by dietary LC n-3 PUFA administered as either triglycerides or phospholipids.
Diet Chow cHF cHF+v3TG cHF+v3PL
DHA/EPA (g per kg diet) - - 30 10 30
Energy balance
Body weight – initial (g) 29.460.7 28.261.2 27.560.8 27.260.9 28.060.6
Body weight – final (g) 31.260.7d 35.762.4 33.661.3 32.361.0 31.562.0
Weight gain (g) 1.8260.67d 7.4962.01 6.0861.26 5.1661.04 3.5061.54
Food intake (kJ/day per animal) ND 6863 6663 6362 6262
WAT
Epididymal fat (mg) 303626d 12686349 11286218 829681 9076276
Adipocyte area (mm2) ND 34136544 28546138 23986168 22226339
Subcutaneous fat (mg) 189610d 414681 402659 331618 356667
Lipid metabolites in plasma
Triacylglycerol (mmol/l) 0.9660.05 1.1260.13 0.9160.13 1.1360.11 0.7160.13a
NEFA (mmol/l) 0.5860.05 0.4460.04 0.3060.02a 0.4760.05b 0.2760.04ac
Cholesterol (mmol/l) 1.6760.03d 3.3460.34 2.9260.28 3.0460.22 2.9460.30
Glucose homeostasis
Glucose (mmol/l) 9.0860.71 10.7760.54 10.8760.55 11.3660.58 10.5560.48
FBG (mmol/l) 4.7560.39 5.1560.22 5.3460.26 4.8260.20 4.7060.17
AUC glucose (mmol ? 180 min) 1517692d 2221678 2299684 1760663ab 1831684ab
Plasma insulin (pmol/l) 9769d 318663 246647 166625 159624
Adiponectin - HMW (A.U.) ND 0.6060.11 0.8860.10 0.8460.09 0.9360.09
HMW: total ND 0.3760.04 0.4460.04 0.4460.03 0.4760.03
Tissue triacylglycerol
Liver (mg/g) ND 4167 3664 2262a 2764a
Skeletal muscle (mg/g) ND 2363 1764 1162 1763
Mice (3-months-old) were placed on various diets and killed after nine weeks of the dietary treatment. Body weight gain was calculated as the difference in body weight
between the beginning of the experiment and after eight weeks of treatment. Food intake was monitored weekly during weeks 2 to 8 of the dietary treatment. As
shown before [8,58], there was no difference in food intake between the Chow- and cHF-fed mice. Glucose homeostasis was assessed by glucose tolerance test in mice
fasted overnight after eight weeks of treatment (see Fig. S1). Data are means6SEM (n= 7).
a,b,cSignificant differences (ANOVA) compared with cHF, cHF+v3TG, and cHF+v3PL (10 g per kg diet), respectively;
dp#0.05 vs. cHF (t-test).
AU, arbitrary units; AUC, area under the glucose curve; FBG, fasting blood glucose; HMW: total, ratio of high molecular weight to total adiponectin; ND, not determined;
NEFA, non-esterified fatty acids; WAT, white adipose tissue.
doi:10.1371/journal.pone.0038834.t001
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suppressed by both the cHF+v3TG- and cHF+v3PL-treatment.
In contrast, tissue levels of N-eicosapentaenoylethanolamine
(EPEA) and N-docosahexaenoylethanolamine (DHEA), i.e. anti-
inflammatory molecules derived from EPA and DHA respectively,
were induced by both treatments, with the cHF+v3PL-treatment
exerting a much stronger effect on DHEA (Fig. 6B). With the
exception of dihomo-c-linolenoylethanolamine, the WAT levels of
other N-acyl ethanolamines did not change in response to LC n-3
PUFA supplementation (Table S11). The changes in the levels of
endocannabinoids and related molecules in WAT closely reflected
those observed in plasma (Table S11). Moreover, when the
average values of 2-AG or DHEA levels in WAT were plotted
against the size of adipocytes in different experimental groups,
a positive relationship was observed in the case of 2-AG (Fig. 6C),
while DHEA showed a negative relationship (Fig. 6D).
These data suggest that 2-AG rather than AEA could contribute
to metabolic abnormalities in obese mice and that, compared with
triglycerides, dietary LC n-3 PUFA administered as phospholipids
are more effective in reducing 2-AG and increasing anti-
inflammatory DHEA in WAT.
Discussion
Given the well-known beneficial effects of LC n-3 PUFA on
health (see the Introduction), it is of the utmost importance to
define the optimal lipid form for delivering these fatty acids into
the organism. We show here that dietary DHA and EPA
supplemented as phospholipids were more efficient than triglycer-
ides in ameliorating obesity-associated pathologies, including
impaired glucose homeostasis, hepatic steatosis and dyslipidemia,
as well as adipocyte hypertrophy and low-grade inflammation of
WAT in mice fed a high-fat diet.
It is relatively difficult to compare the biological effectiveness
of individual components of complex mixtures, as in case of the
LC n-3 PUFA concentrates from marine fish used here. Thus, in
the ‘prevention study’, assuming that LC n-3 PUFA are the
major active constituents, cHF+v3TG and cHF+v3PL treat-
ments were compared using diets matched for total DHA/EPA
content (30 g per kg diet). Due to a higher DHA/EPA level in
the triglyceride than in the phospholipid concentrate, a higher
portion of dietary lipids had to be replaced by the phospholipid
concentrate in order to achieve an equal dietary DHA/EPA
content. Despite this fact, the ratios of total n-6 PUFA to n-3
PUFA in the two diets were quite similar. In order to eliminate
a possible confounding effect of differential dilutions of corn oil
(high in LA, i.e. n-6 PUFA) as in the case of triglyceride and
phospholipid concentrates, the cHF+v3PL-treatment was also
performed at a 3-fold lower dietary DHA/EPA content (10 g
DHA/EPA per kg diet), i.e. ,30% less dietary lipids were
replaced by the phospholipid concentrate as compared with the
cHF+v3TG diet containing 30 g DHA/EPA per kg diet.
Irrespectively of the DHA/EPA content, both cHF+v3PL
treatments preserved glucose tolerance and prevented hepatic
steatosis, while the cHF+v3TG-treatment did not. This made it
possible to exclude the possibility that a higher efficacy of the
phospholipid-based treatment was the result of a higher content
Figure 2. Bioavailability of DHA and EPA and their accumulation in the liver and WAT in the ‘prevention study’. A,B Fatty acid (FA)
composition of total lipids in plasma was analyzed in mice fed for 2 weeks with the cHF+v3TG (red circles) or cHF+v3PL (blue circles) diet with
various concentrations of DHA/EPA. The correlation plots between dietary content and the corresponding increments in plasma concentrations of
DHA (A) and EPA (B) corrected for the values in the cHF-fed mice (DHA, 2.49–2.84 mol %; EPA, 0.05–0.16 mol %; see also Fig. 2C,D). The coefficient of
determination (R2), describing the proportion of the dependent variable that is explained by the independent variable, is also shown. The
concentration of DHA (C) and EPA (D) in total plasma lipids, liver triglycerides (TG) and phospholipid (PL) fraction, and in total lipids from epididymal
white adipose tissue (WAT) was assessed in mice from the ‘prevention study’ following 9 weeks of feeding cHF+v3TG (red bars) and cHF+v3PL (blue
bars) diets supplemented with 30 g DHA/EPA per kg, or the control cHF diet (black bars). For the detailed data on fatty acid composition, see Tables
S4, S5, S6, S7). Data are means6SEM (n=427); if SEM is not shown, it is smaller than the symbol size (A,B). *Significantly different from cHF+v3TG
(ANOVA).
doi:10.1371/journal.pone.0038834.g002
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of the concentrate in the diet rather than of qualitative
differences between the LC n-3 PUFA concentrates. Moreover,
when using the DHA/EPA-matched diets (i.e. 30 g DHA/EPA
per kg), the cHF+v3PL-treatment tended to exert stronger
beneficial effects on weight gain, adiposity and fat cell size,
plasma triglycerides, fasting glycemia and insulinemia.
In the ‘reversal study’, body weight, hepatic steatosis, adipocyte
hypertrophy and low-grade inflammation of WAT were more
potently reduced by the cHF+v3PL-treatment. In contrast to the
prevention study, blood glucose levels in obese mice were lowered
to a similar extent by both treatments. However, only the
cHF+v3PL-treatment significantly decreased plasma insulin.
Future experiments should therefore focus on detailed character-
isation of changes in insulin sensitivity brought about by dietary
phospholipids.
In line with previous studies [30–34], our results document
better bioavailability of both DHA and EPA when supplemented
as dietary phospholipids and this effect can largely be attributed to
a marked improvement in EPA bioavailability (see also ref. [34]).
Accordingly, in humans, most orally administered PC is hydro-
lysed to lysoPC before absorption [39]. This in turn is well
absorbed and may augment LC n-3 PUFA delivery [40].
However, similar ratio between EPA and DHA content was
found in the PC and the lysoPC fraction from the marine
phospholipid concentrate used in our study, suggesting that the
differences in EPA and DHA bioavailability could not be
explained by their absorption via the lysoPC molecule.
In agreement with the previous observation in both humans
[41] and mice [42], saturable incorporation of DHA into total
plasma lipids was observed, while a linear relationship between
dietary concentration of EPA and its plasma level was found,
which contributed to a relatively high bioavailability of EPA from
the phospholipid concentrate. The difference in bioavailability was
not reflected in changes in DHA and EPA in the composition of
either liver or WAT triglycerides. However, in total liver
phospholipids, EPA accumulated more and AA less in the
cHF+v3PL-treated mice than in the cHF+v3TG-treated mice.
The differences between the two treatments became apparent
when the TOF-SIMS analysis was conducted. PE, PI and PC
phospholipid species, such as PE 38:6, PE 40:6 and PI 38:5 in the
Figure 3. Changes in the lipid spectra in response to dietary LC n-3 PUFA in selected tissues of mice in the ‘prevention study’. Mice
were fed for 9 weeks the cHF (black triangles), cHF+v3TG (red circles), or cHF+v3PL (blue circles) diet, while the last two diets were supplemented
with 30 g DHA/EPA per kg. In total, 59, 71 and 61 lipid species were quantified in the liver, epididymal WAT and skeletal muscle, respectively, using
time-of-flight secondary ion mass spectrometry (TOF-SIMS) analysis (see also Table S8, S9, S10). Means6SEM of 3–6 TOF-SIMS spectra from 3
animals per each group were used for orthogonal partial least squares-discriminant analysis (oPLS-DA). Score plots of the liver (A), WAT (B) and
skeletal muscle (C) and corresponding variable important to projection (VIP) plots for the first latent variable (D, E, F), respectively. Only variables
with VIP scores greater than 1 (denoted by a dashed horizontal line; D-F) and narrow confidence intervals were used for further evaluations, and only
those discriminating between cHF+v3TG and cHF+v3PL diets (gray bars, D-F) were plotted (G; cHF diet, black bars; cHF+v3TG diet, red bars;
cHF+v3PL diet; blue bars). See also Fig. S3 for additional lipid species identified. DAG, diacylglycerol. *Significantly different from cHF (all analyses by
ANOVA).
doi:10.1371/journal.pone.0038834.g003
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liver and PE 40:6 in WAT, were the discriminating analytes. It is
likely that these phospholipid species are enriched with DHA,
since it has previously been shown that, in egg phospholipids from
hens fed on seal blubber oil [43,44], there is a preferential
incorporation of DHA into the PE, PI, and PC fraction [43],
especially in the sn-2 position of the phospholipid molecule [44].
These data are consistent with the notion that cell membrane
phospholipids represent an important reservoir of DHA and EPA
and their processing into lipid signalling molecules [9,20,22], and
they suggest that the difference in the effectiveness of the
treatments is largely explained by differential accumulation of
DHA and EPA in specific phospholipid molecules (see also [4]). It
is also likely that the more potent reductions of AA in the
phospholipid and diacylglycerol pools associated with (i) AA
replacement in membrane phospholipids by LC n-3 PUFA (for
reviews, see [45,46]), and (ii) lower dietary content of LA, which is
the precursor of AA, contribute to the superior anti-inflammatory
effects of the cHF+v3PL-treatment. This could be due to a lower
formation of both, the pro-inflammatory mediators and endocan-
nabinoids derived from AA.
In line with previous data on krill oil [11,25,26,35], our results
support the notion that the endocannabinoid system is involved in
the mechanism of action of LC n-3 PUFA. Levels of 2-AG in
WAT were more efficiently reduced by LC n-3 PUFA adminis-
tered as phospholipids, which was paralleled by decreased levels of
AA in the diacylglycerol fraction, attesting to the latter’s precursor
role in 2-AG synthesis [23]. In contrast to another report [25], the
levels of AEA in WAT were relatively low and were further
reduced by LC n-3 PUFA in the diet. Therefore, as is the case in
humans [24], it is unlikely that AEA contributes significantly to
metabolic derangements in dietary obese mice. Dietary phospho-
lipids also induced adipose levels of N-acyl ethanolamines EPEA
and especially DHEA, i.e. the metabolites of EPA and DHA,
respectively, more strongly and effectively than triglycerides. The
pathophysiological role of the endocannabinoid system in the
development of adipose tissue inflammation [47] or hepatic
steatosis [48,49] is well described, and anti-inflammatory effects of
adipocyte-derived EPEA or DHEA have recently been suggested
[50,51]. Average daily food intake was slightly but insignificantly
decreased in the cHF+v3PL-treated mice, however the levels of N-
oleoylethanolamine, i.e. the endocannabinoid that is known to
suppress food intake [52], were completely unchanged both in
WAT and plasma of these mice. Thus, our results are in
agreement with a specific role of the dysregulated endocanna-
binoid system in WAT in the pathophysiology of metabolic
syndrome [24,26].
In fact, the increase in obesity prevalence in the United States
during the 20th century could be in part due to the elevated
consumption of LA, the precursor of AA, and hence also the
precursor of the AA-derived endocannabinoids [53,54]. Very
recently, this idea was supported by dietary experiments in mice
fed various diets differing in the LA content [54]. This content
was positively correlated with the levels of AA, 2-AG and AEA in
phospholipids isolated both from the liver and erythrocytes, while
dietary LA also promoted accumulation of body fat. In
accordance with our results in plasma and WAT, addition of
EPA and DHA to the diet resulted in a decrease of
endocannabinoid levels in the liver and also in hypothalamus
of mice fed experimental diets with a high LA content [54].
Accordingly, we have observed before in mice that supplemen-
tation of a high-fat diet by LC n-3 PUFA, under very similar
conditions as used in the ‘prevention study’ here, reduced body
fat depots when LA formed 53% of dietary lipids, but did not
affect adiposity when the LA content represented 15% of dietary
fat [55]. Taken together, the data further support the role of
dietary LA as the key factor controlling the activity of the
endocannabinoid system, and the attenuation of the endocanna-
binoid system activity as the key mechanism underlying anti-
obesity effects of dietary LC n-3 PUFA supplementation under
these conditions. However, precise involvement of various tissues
in the metabolic impact of attenuated endocannabinoid system
activity in response to LC n-3 PUFA should be better
characterized [23]. Moreover, conflicting data exist regarding
the potential role of dietary macronutrient composition in the
anti-obesity effects of LC n-3 PUFA [56,57]. Nevertheless, the
data also suggest that the experimental model of obesity induced
in mice by feeding a high-fat diet containing high levels of LA, as
used in our current study as well as in most of our previous
Table 2. Reversal of obese phenotype by dietary LC n-3 PUFA
administered as either triglycerides or phospholipids.
Diet cHF cHF+v3TG cHF+v3PL
Energy balance
Body weight – initial (g) 40.261.5 38.561.9 41.261.1
Body weight – final (g) 46.062.2 41.162.3 41.261.5
Weight gain (g) 5.8460.96 2.6760.53a 0.0460.65ab
Food intake (kJ/day per
animal)
7265 6763 6261
WAT
Epididymal fat (mg) 24406206 19066231a 19786164a
Subcutaneous fat (mg) 12886188 10076149 9326108
Lipid metabolites in plasma
Triglycerides (mmol/l) 1.0960.08 0.7860.12a 0.6660.04a
NEFA (mmol/l) 1.3560.06 0.9860.10a 0.9460.04a
Cholesterol (mmol/l) 4.0660.29 3.1660.38a 3.3760.20a
Glucose homeostasis
Glucose (mmol/l) 11.9260.70 9.7460.37a 9.9360.53a
FBG (mmol/l) 8.2660.67 6.0260.30a 5.9460.33a
AUC glucose (mmol ? 180 min)30646189 26506179 26576160
Plasma insulin (pmol/l) 307655 223652 156618a
Adiponectin - HMW (A.U.) 0.5460.05 1.0160.12a 1.0060.17a
HMW: total 0.4260.02 0.5160.02a 0.5360.02a
Tissue triglycerides
Skeletal muscle (mg/g) 2966 1362a 1061a
To induce obesity, dyslipidemia and glucose intolerance, mice were fed a cHF
diet between three and seven months of age, and then for nine more weeks on
different diets (all containing 2 g metformin per kg diet). cHF+v3TG and
cHF+v3PL diets were supplemented with ,30 g DHA/EPA per kg diet. No
significant differences between metformin-supplemented cHF diet and the cHF
diet alone were observed with regard to any of the parameters shown above
(e.g. cHF alone - weight gain: 46.062.0 g; epididymal WAT: 21606204 mg;
plasma triglycerides: 1.1160.05 mmol/l; AUC glucose: 33956231 mmol x
180 min; and plasma insulin: 400647 pmol/l; not shown). Body weight gain
was calculated as the difference in body weight between the beginning of the
experiment and after eight weeks of treatment. Food intake was monitored
weekly during weeks 2 to 8 of the dietary treatment. Glucose homeostasis was
assessed by a glucose tolerance test in mice fasted overnight after eight weeks
of treatment.
Data are means6SEM (n= 8–9).
a,bSignificant differences (ANOVA) compared with cHF and cHF+v3TG,
respectively. AU, arbitrary units; AUC, area under the glucose curve; FBG, fasting
blood glucose; HMW: total, ratio of high molecular weight to total adiponectin;
NEFA, non-esterified fatty acids; WAT, white adipose tissue.
doi:10.1371/journal.pone.0038834.t002
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studies [8–10,12,58], is highly relevant for understanding the
beneficial metabolic effects of LC n-3 PUFA supplementation in
humans consuming an obesogenic Western diet.
Cannabinoid receptor 1 antagonist rimonabant has been used
to effectively treat obesity. It had to be withdrawn from clinical
practice, however, due to adverse side effects on the central
nervous system. Selective blocking of the peripheral endocanna-
binoid system might nevertheless represent an effective and safe
therapy [24,59]. In this respect, modulation of the endocanna-
binoid system in the peripheral tissues by LC n-3 PUFA
administered as phospholipids should be further explored. With
regard to treatment strategies for obesity-associated disorders,
combined treatment using LC n-3 PUFA as triglycerides and
pharmaceuticals like thiazolidinediones has been shown to be
very effective [8,58]. The inclusion of LC n-3 PUFA as
phospholipids might increase the efficacy of such treatment by
more potently modulating the activity of the peripheral
endocannabinoid system.
To preserve health, most of the nutritional and cardiological
societies worldwide recommend to increase intake of fatty sea
fish, which contain LC n-3 PUFA in both the triacylglycerol
and phospholipid form. Nutritional supplements containing LC
n-3 PUFA as triglycerides (or ethyl-esters) are also considered
[60]. Our results are in favour of this strategy and they suggest
that the efficacy of the supplements could be further augmented
based on the use of marine-derived phospholipids.
In conclusion, compared with triglycerides, dietary LC n-3
PUFA as phospholipids from marine fish exert superior
metabolic effects in the context of high-fat diet-induced obesity
in mice. Dietary supplementation of relatively low doses of
DHA and EPA administered as phospholipids resulted in better
bioavailability, while more efficacious lowering of the AA
content in cellular phospholipids resulted in reduced production
of the classical endocannabinoids AEA and 2-AG and increased
production of anti-inflammatory molecules such as EPEA and
DHEA. By multiple mechanisms of action, dietary phospholi-
pids of marine origin might thus substantially improve pre-
vention and treatment strategies for obesity-associated metabolic
disorders.
Figure 4. Reversal of hepatic lipid accumulation by dietary LC n-3 PUFA. Following a 4-month period of cHF-feeding, mice were fed for
additional 9 weeks with cHF diet or treated using either cHF+v3TG or cHF+v3PL diet supplemented with 30 g DHA/EPA per kg; all diets also
contained 2 g metformin per kg. Hematoxyline-eosin staining of liver sections from mice fed cHF (A), cHF+v3TG (B), or cHF+v3PL (C) diet. Hepatic
lipid content (D). Quantification of mRNA levels of fatty acid oxidation (E) and lipogenic (F) genes in mice fed cHF (black bars), cHF+v3TG (red bars),
or cHF+v3PL (blue bars) diets. A-C, Scale bars = 200 mm. AOX, acyl-CoA oxidase; ACOT2, acyl-CoA thioesterase 2; FAS; fatty acid synthase; SCD-1,
stearoyl-CoA desaturase 1. Data are means6SEM (n=7). *Significantly different from cHF (t-test or ANOVA); {significantly different from cHF+v3TG
(ANOVA).
doi:10.1371/journal.pone.0038834.g004
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Materials and Methods
Animals and Treatments
Male C57BL/6J mice (Institute of Physiology, Academy of
Sciences of the Czech Republic, Prague) were weaned on a standard
Chow (extruded Ssniff R/M-H diet; Ssniff Spezialdieten GmbH,
Soest, Germany) and maintained on a 12:12-hr light-dark cycle at
22uC (3–4 animals/cage). To induce obesity, three-month-old mice
were assigned to cHF diet (lipids ,35% wt/wt; mostly corn oil;
virtually DHA/EPA-free; see also ref. [8]). Three different dietary
treatment protocols were used (Fig. 1):
Firstly, a ‘prevention study’ was performed to characterise the
effects of LC n-3 PUFA on the development of obese phenotype,
while replacing part of corn oil in the cHF diet with the LC n-3
PUFA concentrates, either as triacylglycerols (DHA, 46% wt/wt;
EPA, 14% wt/wt; product EPAX 1050 TG; EPAX AS, Aalesund,
Norway; cHF+v3TG diet) or phospholipids from marine fish
(DHA, 17–20% wt/wt; EPA, 5–8% wt/wt; prepared by EPAX
AS; see Tables S1 and S2; cHF+v3PL diet) in order to achieve
a sum of DHA and EPA (DHA/EPA) of 30 g per kg diet. A group
of mice was also treated using a cHF+v3PL diet containing 10 g
DHA/EPA per kg diet. For the fatty acid composition of
experimental diets, see Table S3. The study lasted for a period
of 9 weeks and the cHF-fed mice served as controls. Chow-fed
mice were also analysed. The energy density of the Chow and
isocaloric cHF-based diets was 16.3 and 22.8 kJ per g diet,
respectively.
Secondly, a ‘bioavailability study’ was performed that was
similar to that described above, except that (i) various formulations
of the cHF+v3TG and cHF+v3PL diet were used, in which the
DHA and EPA content varied from 0.9 to 22.5 g DHA per kg diet
and from 0.3 to 8.2 g EPA per kg diet; (ii) these dietary treatments
lasted for only two weeks, and (iii) the cHF-fed but not Chow-fed
mice were used, and served as controls.
Thirdly, in a ‘reversal study’, obesity was induced by cHF
feeding between three and seven months of age prior to 9-week-
long treatment using cHF+v3TG or cHF+v3PL diets supple-
Figure 5. Reversal of adipose tissue hypertrophy and low-grade inflammation by dietary LC n-3 PUFA. Following a 4-month period of
cHF-feeding, mice were fed for additional 9 weeks with cHF diet or treated using either cHF+v3TG or cHF+v3PL diet supplemented with 30 g DHA/
EPA per kg; all diets also contained 2 g metformin per kg. Hematoxyline-eosin staining of epididymal fat sections from mice fed cHF (A), cHF+v3TG
(B), or cHF+v3PL (C) diet. D Adipocyte size; morphometric analysis was based on more than 1,000 cells taken randomly from 5 different areas per
animal (n= 3). E Amount of MAC-2 immunoreactive macrophages in the above tissue sections, expressed as the number of crown-like structures
(CLS; indicated by white arrows in A–C). F Adipose tissue gene expression of monocyte chemoattractant protein-1 (MCP-1), a chemokine which is
involved in the recruitment of monocytes to sites of injury and infection. cHF diet, black bars; cHF+v3TG diet, red bars; cHF+v3PL diet; blue bars. A-C,
Scale bars = 200 mm. Data are means6SEM (n= 728; D–F). *Significantly different from cHF; {significantly different from cHF+v3TG (all analyses by
ANOVA).
doi:10.1371/journal.pone.0038834.g005
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mented with 30 g DHA/EPA per kg diet; the cHF-fed mice
served as controls. In this study, all the diets (i.e. cHF,
cHF+v3TG, and cHF+v3PL) also contained 2 g metformin
per kg diet (Tables S1,S2).
Body weight was monitored weekly, while a fresh ration was
given every two days. The food intake of a group of mice (3 to 4
mice/cage), assessed once weekly during a 24-hr period, was
averaged per mouse during weeks 2 to 8 after the start of
differential dietary treatment. Mice were killed by cervical
dislocation under diethylether anesthesia between 9 and 11 a.m.
Dorsolumbar (subcutaneous) and epididymal (abdominal) WAT,
the liver and skeletal muscle (m. quadriceps femoris) were dissected
and snap-frozen in liquid nitrogen. Tissues and EDTA-plasma
from truncal blood were stored at –70uC. Animal experiments
were approved by the Animal Care and Use Committee of the
Institute of Physiology Academy of Sciences of the Czech Republic
v.v.i. (Approval Number: 58/2009) and followed the guidelines.
Plasma Metabolites, Hormones and Enzymes
Plasma triglycerides, total cholesterol, NEFA and insulin were
determined as before [8]. The distribution of adiponectin multi-
meric complexes in plasma was determined by Western blotting
[61].
Glucose Tolerance Test
An intraperitoneal glucose tolerance test was performed on
fasted mice as described before [12].
Quantitative RT-PCR-based Analysis
An analysis of levels of various transcripts in total RNA isolated
from liver and epididymal fat was performed and normalised as
before [3]. The sequences of oligonucleotide primers have been
published before [8,9].
Tissue Lipid Content
Liver and muscle lipid content was estimated in ethanolic KOH
tissue solubilisates [12].
Light Microscopy and Immunohistochemical Analysis
Samples of epididymal fat and liver were fixed in 4%
formaldehyde, embedded in paraffin, and 5 mm-sections were
stained using hematoxylin-eosine. In epididymal fat, a macrophage
marker, MAC-2/galectin-3, was also detected using specific
antibodies [8]. Digital images were captured using Olympus
AX70 light microscope and a DP 70 camera (Olympus, Tokyo,
Japan). Adipocyte morphometry was performed using a Lucia
IMAGE version 4.81 (Laboratory Imaging, Prague, Czech
Republic).
Plasma and Tissue Fatty Acid Composition in Lipid
Fractions
The fatty acid composition of total lipid fraction from diets,
plasma and epididymal fat, as well as of triglyceride and total
phospholipid fractions from the liver, was analysed using gas
chromatography [36]. TOF-SIMS analysis [37,38] was applied to
analyse free fatty acids and the fatty acid composition of the
triglyceride, diacylglycerol, PC, PE and PI fractions from the liver,
epididymal fat and skeletal muscle.
Endocannabinoid Levels
The levels of 2-AG, AEA, DHEA, EPEA, oleoylethanolamine,
palmitoylethanolamine, stearoylethanolamine and dihomo-c-lino-
lenoylethanolamine were quantified, either in individual samples
of epididymal fat (,100 mg) or in pooled samples (,0.1 ml) of
EDTA-plasma using LC-MS/MS. Tissues and plasma were
extracted with acetonitrile containing the appropriate internal
Figure 6. Modulation of adipose tissue levels of endocannabinoids and endocannabinoid-like molecules by dietary LC n-3 PUFA in
the ‘reversal study’. Following a 4-month-period of cHF-feeding, mice were fed for additional 9 weeks cHF diet, or treated using either cHF+v3TG
or cHF+v3PL diet supplemented with 30 g DHA/EPA per kg; all diets also contained 2 g metformin per kg. The effects of LC n-3 PUFA
supplementation on adipose tissue levels of 2-arachidonoylglycerol (2-AG) and anandamide (AEA; A), as well as on the levels of N-
eicosapentaenoylethanolamine (EPEA) and N-docosahexaenoylethanolamine (DHEA; B); cHF, black bars; cHF+v3TG, red bars; cHF+v3PL, blue bars.
The relationship between adipocyte size and adipose tissue levels of either 2-AG (C) or DHEA (D) in mice fed cHF (black triangles), cHF+v3TG (red
circles), or cHF+v3PL (blue circles) diet. Data are means6SEM (n= 8–9). *Significantly different from cHF (t-test or ANOVA); {significantly different
from cHF+v3TG (ANOVA).
doi:10.1371/journal.pone.0038834.g006
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standards. Tissue extracts were analysed on a Quantum TSQ
(Thermo, Breda, The Netherlands) LC-MS, while plasma extracts
were analysed on a Xevo TQ-S (Waters, Etten-Leur, The
Netherlands) LC-MS.
Statistical Analysis
All values are presented as means6SEM. Logarithmic trans-
formation was used to stabilise variance in cells when necessary.
Data were analysed by paired t-test or ANOVA (one-way or two-
way) with Holm-Sidak post-hoc tests using SigmaStat 3.5 statistical
software. Comparisons were judged to be significant at p#0.05.
Lipidomic data were evaluated using oPLS-DA and Umetrics
SIMCA-P+12 statistical software (Umetrics AB, Umea˚, Sweden).
Supporting Information
Figure S1 Glucose tolerance in response to dietary LC
n-3 PUFA administered to mice in the ‘prevention
study’. Mice were fed for 9 weeks a corn oil-based high-fat
(cHF; black circles) diet, or experimental cHF+v3TG (red circles)
and cHF+v3PL (blue triangles) diets containing 30 g DHA/EPA
per kg diet. Some mice were also fed a low-fat Chow diet (grey
circles). Plasma glucose profiles during 180 min following i.p.
injection of glucose (time 0). Data are means6SEM.
(TIF)
Figure S2 Orthogonal Partial Least Squares - Discrim-
inant Analysis (Opls-DA) of fatty acid composition data
in the liver and adipose tissue of mice in the ‘prevention
study’. Mice were fed for 9 weeks a corn oil-based high-fat (cHF;
black triangles) diet or cHF-based experimental diets, in which
part of dietary lipids was replaced by LC n-3 PUFA concentrates
either in the form of triglycerides (cHF+v3TG; red circles) or
marine phospholipids (cHF+v3PL; blue circles) to achieve dietary
EPA and DHA concentration of 30 g per kg diet. In total, 22 and
17 fatty acids were quantified in the phospholipid fraction from the
liver and in total lipids from adipose tissue, respectively, using gas
chromatography (see also Tables S6 and S7). To identify the major
fatty acids discriminating between the cHF+v3TG and
cHF+v3PL groups, multivariate analysis was performed on fatty
acid profiles in liver phospholipids (A,B) and total lipids in adipose
tissue (C,D) using the oPLS-DA algorithm. Within each tissue,
mice (n= 427) were separated into 3 distinct groups based on the
diet (A,C), and variables important to the projection of the first
latent variable were plotted (B,D). To identify the most important
ones, only variables with VIP scores greater than 1 (denoted by
a solid horizontal line; B and D) and narrow confidence intervals
were used for further evaluations (interpretations).
(TIF)
Figure S3 The levels of lipid species discriminating
betweeen the phospholipid and triglyceride LC n23
PUFA supplementation in the liver, adipose tissue and
muscle of mice in the ‘prevention study’. Mice were fed for
9 weeks a corn oil-based high-fat (cHF; black bars) diet or cHF-
based experimental diets, in which part of dietary lipids was
replaced by LC n23 PUFA concentrates either in the form of
triglycerides (cHF+v3TG; red bars) or phospholipids (cHF+v3PL;
blue bars) to achieve dietary EPA and DHA concentration of 30 g
per kg diet. In total, 59, 71 and 61 lipid species were quantified in
the liver, adipose tissue and skeletal muscle, respectively, using the
TOF-SIMS analysis (see also Tables S82S10). Major lipid species
discriminating between the cHF+v3TG and cHF+v3PL groups
were identified by the oPLS-DA algorithm.
(TIF)
Table S1 Diets and treatments. cHF-based experimental
diets were supplemented with the EPA and DHA concentrates
either in the form of triglycerides (cHF+v3TG diet) or marine
phospholipids (cHF+v3PL diet) to achieve various dietary EPA
and DHA concentrations. In the ‘reversal study‘, all diets were also
supplemented by 2 g metformin per kg diet. The concentrates
were dissolved in corn oil prior to the preparation of experimental
diets. aPercentage of dietary lipids replaced by EPAX 1050 TG
(containing 46% DHA and 14% EPA). bPercentage of dietary
lipids replaced by marine phospholipids (containing 20% DHA
and 8% EPA). cPercentage of dietary lipids replaced by EPAX
1050 TG (containing 46% DHA and 14% EPA). dPercentage of
dietary lipids replaced by marine phospholipids (containing 17%
DHA and 5% EPA). See Table S2 for further details on the
composition of marine phospholipids. -, not used in the respective
study.
(DOC)
Table S2 Phospholipid and fatty acid composition of
the EPA and DHA concentrate based on marine phos-
pholipids. Food grade herring meal was extracted once with
ethanol (ethanol/meal = 5:1 vol/wt) at 60uC. The extract was
concentrated to dryness in vacuo on a rotary evaporator. The
resulting residue was treated with ice cold acetone to extract the
bulk of neutral lipids from the marine phospholipid concentrate
with the EPA and DHA content of 50280 and 1702200 mg per g
diet, respectively. Total phospholipid content in the marine
phospholipid concentrate was 74280% (of three different
analyses), while the content of major phospholipid fractions in
the concentrate was as follows: phosphatidylcholine (PC;
47256%), lysoPC (,3%), phosphatidylethanolamine (PE;
9213), lysoPE (223%). Other minor phospholipid fractions in
the product include phosphatidylinositol (,1%), sphingosine
(224%), and unidentified fraction (2–9%). Fatty acid composition
(mol %) of a typical batch determined by gas chromatography is
shown. MUFA, monounsaturated fatty acids. –, #0.1% (detection
limit).
(DOC)
Table S3 Fatty acid composition of experimental diets
in the ‘prevention study’. cHF-based experimental diets were
supplemented with the EPA and DHA concentrates either in the
form of triglycerides (cHF+v3TG diet) or marine phospholipids
(cHF+v3PL diet) to achieve various dietary EPA and DHA
concentrations. Fatty acid composition (mol %) was analyzed in
triplicates in the total lipid fraction extracted from the experi-
mental diets. Standard errors are not shown, but for most fatty
acids represented ,5% of the mean. SFA, saturated fatty acids;
MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids. –, #0.1% (detection limit).
(DOC)
Table S4 Fatty acid composition of plasma in the
‘prevention study’. Fatty acid composition was analyzed in
the total lipid fraction extracted from plasma. The results (mol %)
are expressed as means 6 SEM (n= 4). a,b,cSignificant differences
(ANOVA) compared with cHF, cHF+v3TG, and cHF+v3PL
(10 g per kg diet), respectively. Similar results were obtained when
fatty acid composition in plasma was analyzed already after
2 weeks of dietary intervention (not shown). MUFA, mono-
unsaturated fatty acids; PUFA, polyunsaturated fatty acids. –,
#0.1% (detection limit).
(DOC)
Table S5 Fatty acid composition of total triglycerides in
the liver from the ‘prevention study’. Fatty acid composi-
n-3 PUFA as Phospholipids
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e38834
tion was analyzed in the triglyceride fraction extracted from the
liver. The results (mol %) are expressed as means 6 SEM (n = 4).
a,b,cSignificant differences (ANOVA) compared with cHF,
cHF+v3TG, and cHF+v3PL (10 g per kg diet), respectively.
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids;
PUFA, polyunsaturated fatty acids. –, #0.1% (detection limit).
(DOC)
Table S6 Fatty acid composition of total phospholipids
in the liver from the ‘prevention study’. Fatty acid
composition was analyzed in the total phospholipid fraction
extracted from the liver. The results (mol %) are expressed as
means 6 SEM (n= 4). a,b,cSignificant differences (ANOVA)
compared with cHF, cHF+v3TG, and cHF+v3PL (10 g per kg
diet), respectively. SFA, saturated fatty acids; MUFA, mono-
unsaturated fatty acids; PUFA, polyunsaturated fatty acids. –,
#0.1% (detection limit).
(DOC)
Table S7 Fatty acid composition in total lipids from
adipose tissue in the ‘prevention study’. Fatty acid
composition was analyzed in the total lipid fraction extracted
from abdominal adipose tissue (epididymal fat depot). Results (mol
%) are expressed as means 6 SEM (n= 7). a,b,cSignificant
differences (ANOVA) compared with cHF, cHF+v3TG, and
cHF+v3PL (10 g per kg diet), respectively. MUFA, monounsat-
urated fatty acids; PUFA, polyunsaturated fatty acids. –, #0.1%
(detection limit).
(DOC)
Table S8 TOF-SIMS analysis of lipid fractions in the
liver from the ‘prevention study’. Various lipid species were
analyzed in the liver by the TOF-SIMS method. Data are
expressed as the (cHF+v3TG)/cHF and (cHF+v3PL)/cHF
normalised signal intensity ratios for lipid signals, originating from
mice fed the control diet (cHF) and from mice fed the cHF-based
experimental diets supplemented with the EPA and DHA
concentrate either in the form of triglycerides (cHF+v3TG) or
marine phospholipids (cHF+v3PL). DAG, diacylglycerol; PC,
phosphatidylcholine; PE, phosphatidylethanolamine; PI, phospha-
tidylinositol.
(DOC)
Table S9 TOF-SIMS analysis of lipid fractions in
adipose tissue from the ‘prevention study’. Various lipid
species were analyzed in epididymal adipose tissue by the TOF-
SIMS method. Data are expressed as the (cHF+v3TG)/cHF and
(cHF+v3PL)/cHF normalised signal intensity ratios for lipid
signals, originating from mice fed the control diet (cHF) and from
mice fed the cHF-based experimental diets supplemented with the
EPA and DHA concentrate either in the form of triglycerides
(cHF+v3TG) or marine phospholipids (cHF+v3PL). DAG,
diacylglycerol; PE, phosphatidylethanolamine.
(DOC)
Table S10 TOF-SIMS analysis of lipid fractions in the
skeletal muscle from the ‘prevention study’. Various lipid
species were analyzed in the skeletal muscle (m. quadriceps femoris) by
the TOF-SIMS method. Data are expressed as the (cHF+v3TG)/
cHF and (cHF+v3PL)/cHF normalised signal intensity ratios for
lipid signals, originating from mice fed the control diet (cHF) and
from mice fed the cHF-based experimental diets supplemented
with the EPA and DHA concentrate either in the form of
triglycerides (cHF+v3TG) or marine phospholipids (cHF+v3PL).
DAG, diacylglycerol; PC, phosphatidylcholine; PE, phosphatidyl-
ethanolamine; PI, phosphatidylinositol.
(DOC)
Table S11 The levels of endocannabinoids and endo-
cannabinoid-like molecules in plasma and epididymal
adipose tissue of dietary obese mice from the ‘reversal
study’. To induce obesity, dyslipidemia and glucose intolerance,
mice were fed the cHF diet between 3 and 7 months of age, and
then for 9 more weeks by different diets (all containing 2 g
metformin per kg diet). cHF+v3TG and cHF+v3PL diets were
supplemented with ,30 g DHA/EPA per kg diet. Data (ng/g
tissue) are expressed as means6SEM (plasma, n= 2 of pooled
samples from 3 mice; adipose tissue, n= 829). aSignificant
differences compared with cHF (t-test or ANOVA). bSignificant
differences compared with cHF+v3TG (ANOVA). 2-AG, 2-
arachidonoylglycerol; AEA, anandamide; DHEA, N-docosahex-
aenoylethanolamine; EPEA, N-eicosapentaenoylethanolamine;
OEA, oleoylethanolamine; PEA, palmitoylethanolamine; SEA,
stearoylethanolamine; DLE, dihomo-c-linolenoylethanolamine.
(DOC)
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